# HIF1α-Induced by Lysophosphatidic Acid Is Stabilized via Interaction with MIF and CSN5

**Authors:** Yi Ran No, Sei-Jung Lee, Ajay Kumar, C. Chris Yun

PMC · DOI: 10.1371/journal.pone.0137513 · PLoS ONE · 2015-09-09

## TL;DR

This study shows how lysophosphatidic acid stabilizes HIF1α in colon cancer cells through a complex involving MIF and CSN5, promoting cancer growth.

## Contribution

The paper identifies a ternary complex of HIF1α, MIF, and CSN5 that stabilizes HIF1α under aerobic conditions in colon cancer.

## Key findings

- LPA transcriptionally regulates MIF expression in colon cancer cells.
- MIF and HIF1α form a reciprocal regulatory relationship under LPA stimulation.
- CSN5 acts as a physical link between HIF1α and MIF to stabilize HIF1α.

## Abstract

Macrophage migration inhibitory factor (MIF) is a cytokine that has broad effects on immune system and inflammatory response. A growing body of evidence implicates the role of MIF in tumor growth and metastasis. Lysophosphatidic acid (LPA), a bioactive lipid mediator, regulates colon cancer cell proliferation, invasion, and survival through LPA2 receptor. Loss of LPA2 results in decreased expression of MIF in a rodent model of colon cancer, but the mechanism of MIF regulation by LPA is yet to be determined. In this study, we show that LPA transcriptionally regulates MIF expression in colon cancer cells. MIF knockdown decreased LPA-mediated proliferation of HCT116 human adenocarcinoma cells without altering the basal proliferation rates. Conversely, extracellular recombinant MIF stimulated cell proliferation, suggesting that the effect of MIF may in part be mediated through activation of surface receptor. We have shown recently that LPA increases hypoxia-inducible factor 1α (HIF1α) expression. We found that MIF regulation by LPA was ablated by knockdown of HIF1α, indicating that MIF is a transcriptional target of HIF1α. Conversely, knockdown of MIF ablated an increase in HIF1α expression in LPA-treated cells, suggesting a reciprocal relationship between HIF1α and MIF. LPA stimulated co-immunoprecipitation of HIF1α and MIF, indicating that their association is necessary for stabilization of HIF1α. It has been shown previously that CSN9 signalosome subunit 5 (CSN5) interacts with HIF1α to stabilize HIF1α under aerobic conditions. We found that LPA did not alter expression of CSN5, but stimulated its interaction with HIF1α and MIF. Depletion of CSN5 mitigated the association between HIF1α and MIF, indicating that CSN5 acts as a physical link. We suggest that HIF1α, MIF, and CSN5 form a ternary complex whose formation is necessary to prevent degradation of HIF1α under aerobic conditions.

## Linked entities

- **Genes:** MIF (macrophage migration inhibitory factor) [NCBI Gene 4282], HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091], COPS5 (COP9 signalosome subunit 5) [NCBI Gene 10987], LPAR2 (lysophosphatidic acid receptor 2) [NCBI Gene 9170]
- **Proteins:** MIF (macrophage migration inhibitory factor), HIF1A (hypoxia inducible factor 1 subunit alpha), COPS5 (COP9 signalosome subunit 5)
- **Chemicals:** lysophosphatidic acid (PubChem CID 5497152), doxorubicin (PubChem CID 31703)
- **Diseases:** colon cancer (MONDO:0002032)

## Full-text entities

- **Genes:** VHL (von Hippel-Lindau tumor suppressor) [NCBI Gene 7428] {aka HRCA1, RCA1, VHL1, pVHL}, CXCR2 (C-X-C motif chemokine receptor 2) [NCBI Gene 3579] {aka CD182, CDw128b, CMKAR2, IL8R2, IL8RA, IL8RB}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, Cd74 (CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)) [NCBI Gene 16149] {aka CLIP, DHLAG, HLADG, Ia-GAMMA, Ii}, Trp53-ps (transformation related protein 53, pseudogene) [NCBI Gene 22060], EIF1 (eukaryotic translation initiation factor 1) [NCBI Gene 10209] {aka A121, EIF-1, EIF1A, ISO1, SUI1}, Cops5 (COP9 signalosome subunit 5) [NCBI Gene 26754] {aka CSN5, Jab1, Mov34, Sgn5}, COPS8 (COP9 signalosome subunit 8) [NCBI Gene 10920] {aka COP9, CSN8, SGN8}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, RHOA (ras homolog family member A) [NCBI Gene 387] {aka ARH12, ARHA, EDFAOB, RHO12, RHOH12}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, KLF5 (KLF transcription factor 5) [NCBI Gene 688] {aka BTEB2, CKLF, IKLF}, CD74 (CD74 molecule) [NCBI Gene 972] {aka CLIP, DHLAG, HLADG, II, Ia-GAMMA, p33}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, Hif1a (hypoxia inducible factor 1, alpha subunit) [NCBI Gene 15251] {aka HIF-1-alpha, HIF1-alpha, HIF1alpha, MOP1, bHLHe78}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, Mif (macrophage migration inhibitory factor (glycosylation-inhibiting factor)) [NCBI Gene 17319] {aka DER6, GIF, Glif}, Klf5 (Kruppel-like transcription factor 5) [NCBI Gene 12224] {aka 4930520J07Rik, Bteb2, CKLF, IKLF}, MIF (macrophage migration inhibitory factor) [NCBI Gene 4282] {aka GIF, GLIF, MMIF}, LPAR2 (lysophosphatidic acid receptor 2) [NCBI Gene 9170] {aka EDG-4, EDG4, LPA-2, LPA2}, Apc (APC, WNT signaling pathway regulator) [NCBI Gene 11789] {aka CC1, Min, mAPC}, COPS5 (COP9 signalosome subunit 5) [NCBI Gene 10987] {aka CSN5, JAB1, MOV-34, SGN5}, SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, Lpar2 (lysophosphatidic acid receptor 2) [NCBI Gene 53978] {aka Edg4, IPA2, LPA2}, Ccl2 (C-C motif chemokine ligand 2) [NCBI Gene 20296] {aka HC11, JE, MCAF, MCP-1, MCP1, SMC-CF}, Ptgs2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 19225] {aka COX2, Cox-2, PES-2, PGHS-2, PHS II, PHS-2}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852] {aka CD184, D2S201E, FB22, HM89, HSY3RR, LCR1}, CDKN1B (cyclin dependent kinase inhibitor 1B) [NCBI Gene 1027] {aka CDKN4, KIP1, MEN1B, MEN4, P27KIP1}
- **Diseases:** metastasis (MESH:D009362), colon carcinogenesis (MESH:D063646), colorectal adenomas (MESH:D000236), hypoxia (MESH:D000860), inflammatory bowel diseases (MESH:D015212), atherosclerosis (MESH:D050197), septic shock (MESH:D012772), Colitis (MESH:D003092), colon cancer (MESH:D015179), inflammatory (MESH:D007249), acute (MESH:D000208), hypoxic (MESH:D002534), breast cancer (MESH:D001943), rheumatoid arthritis (MESH:D001172), cancer (MESH:D009369)
- **Chemicals:** Agarose (MESH:D012685), McCoy's 5A Medium (MESH:C113109), LPA (MESH:C032881), agar (MESH:D000362), ice (MESH:D007053), CO2 (MESH:D002245), Bicinchoninic Acid (MESH:C047117), lipid (MESH:D008055), SDS (MESH:D012967), puromycin (MESH:D011691), fatty acid (MESH:D005227), hygromycin (MESH:C026273), oxygen (MESH:D010100), paraformaldehyde (MESH:C003043), DMSO (MESH:D004121), Triton X-100 (MESH:D017830), crystal violet (MESH:D005840), PBS (MESH:D007854), (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (-), MG-132 (MESH:C072553), TRIzol (MESH:C411644),  (MESH:D008246),  (MESH:D008263),  (MESH:C515598)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Rodentia (rodent, order) [taxon 9989]
- **Mutations:** -173 G/C
- **Cell lines:** HT-29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0320), SW480 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0546), HCT116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), CT26 — Mus musculus (Mouse), Mouse colon adenocarcinoma, Cancer cell line (CVCL_7254), pLKO.1 — Mus musculus (Mouse), Hybridoma (CVCL_C7RB), LoVo — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0399), HT-19 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0323), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), colon 26 — Mus musculus (Mouse), Mouse colon adenocarcinoma, Cancer cell line (CVCL_0240), MIA-PaCa-2 — Homo sapiens (Human), Pancreatic undifferentiated carcinoma, Cancer cell line (CVCL_0428)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC4564097/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC4564097/full.md

## References

48 references — full list in the complete paper: https://tomesphere.com/paper/PMC4564097/full.md

---
Source: https://tomesphere.com/paper/PMC4564097